The Involvement of PPARs in the Peculiar Energetic Metabolism of Tumor Cells

被引:25
作者
Antonosante, Andrea [1 ]
d'Angelo, Michele [1 ]
Castelli, Vanessa [1 ]
Catanesi, Mariano [1 ]
Iannotta, Dalila [1 ]
Giordano, Antonio [2 ,3 ]
Ippoliti, Rodolfo [1 ]
Benedetti, Elisabetta [1 ]
Cimini, Annamaria [1 ,2 ,4 ]
机构
[1] Univ Aquila, Dept Life Hlth & Environm Sci, I-67100 Laquila, Italy
[2] Temple Univ, Dept Biol, Sbarro Inst Canc Res & Mol Med, Philadelphia, PA 19122 USA
[3] Univ Siena, Dept Med Surg & Neurosci, I-53100 Siena, Italy
[4] Natl Inst Nucl Phys INFN, Gran Sasso Natl Lab LNGS, I-67100 Assergi, Italy
关键词
nuclear receptors; energy metabolism; cancer metabolism; PROLIFERATOR-ACTIVATED-RECEPTOR; CHRONIC LYMPHOCYTIC-LEUKEMIA; FATTY-ACID OXIDATION; BREAST-CANCER CELLS; PYRUVATE-DEHYDROGENASE KINASE; HUMAN HEPATOCELLULAR-CARCINOMA; PALMITOYLTRANSFERASE I GENE; HYPOXIA-INDUCIBLE FACTOR; ELEMENT-BINDING PROTEIN; DELTA PROMOTES SURVIVAL;
D O I
10.3390/ijms19071907
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Energy homeostasis is crucial for cell fate, since all cellular activities are strongly dependent on the balance between catabolic and anabolic pathways. In particular, the modulation of metabolic and energetic pathways in cancer cells has been discussed in some reports, but subsequently has been neglected for a long time. Meanwhile, over the past 20 years, a recovery of the study regarding cancer metabolism has led to an increasing consideration of metabolic alterations in tumors. Cancer cells must adapt their metabolism to meet their energetic and biosynthetic demands, which are associated with the rapid growth of the primary tumor and colonization of distinct metastatic sites. Cancer cells are largely dependent on aerobic glycolysis for their energy production, but are also associated with increased fatty acid synthesis and increased rates of glutamine consumption. In fact, emerging evidence has shown that therapeutic resistance to cancer treatment may arise from the deregulation of glucose metabolism, fatty acid synthesis, and glutamine consumption. Cancer cells exhibit a series of metabolic alterations induced by mutations that lead to a gain-of-function of oncogenes, and a loss-of-function of tumor suppressor genes, including increased glucose consumption, reduced mitochondrial respiration, an increase of reactive oxygen species, and cell death resistance; all of these are responsible for cancer progression. Cholesterol metabolism is also altered in cancer cells and supports uncontrolled cell growth. In this context, we discuss the roles of peroxisome proliferator-activated receptors (PPARs), which are master regulators of cellular energetic metabolism in the deregulation of the energetic homeostasis, which is observed in cancer. We highlight the different roles of PPAR isotypes and the differential control of their transcription in various cancer cells.
引用
收藏
页数:30
相关论文
共 196 条
  • [1] Diverging regulation of pyruvate dehydrogenase kinase isoform gene expression in cultured human muscle cells
    Abbot, EL
    McCormack, JG
    Reynet, C
    Hassall, DG
    Buchan, KW
    Yeaman, SJ
    [J]. FEBS JOURNAL, 2005, 272 (12) : 3004 - 3014
  • [2] The role of lipid droplets and adipocytes in cancer. Raman imaging of cell cultures: MCF10A, MCF7, and MDA-MB-231 compared to adipocytes in cancerous human breast tissue
    Abramczyk, Halina
    Surmacki, Jakub
    Kopec, Monika
    Olejnik, Alicja Klaudia
    Lubecka-Pietruszewska, Katarzyna
    Fabianowska-Majewska, Krystyna
    [J]. ANALYST, 2015, 140 (07) : 2224 - 2235
  • [3] PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth
    Abu Aboud, Omran
    Donohoe, Dallas
    Bultman, Scott
    Fitch, Mark
    Riiff, Tim
    Hellerstein, Marc
    Weiss, Robert H.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2015, 308 (11): : C890 - C898
  • [4] Inhibition of PPARα Induces Cell Cycle Arrest and Apoptosis, and Synergizes with Glycolysis Inhibition in Kidney Cancer Cells
    Abu Aboud, Omran
    Wettersten, Hiromi I.
    Weiss, Robert H.
    [J]. PLOS ONE, 2013, 8 (08):
  • [5] Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer
    Ahmad, Imran
    Mui, Ernest
    Galbraith, Laura
    Patel, Rachana
    Tan, Ee Hong
    Salji, Mark
    Rust, Alistair G.
    Repiscak, Peter
    Hedley, Ann
    Markert, Elke
    Loveridge, Carolyn
    van der Weyden, Louise
    Edwards, Joanne
    Sansom, Owen J.
    Adams, David J.
    Leung, Hing Y.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2016, 113 (29) : 8290 - 8295
  • [6] Peroxisome proliferator-activated receptor (PPAR)β/δ, a possible nexus of PPARα- and PPARγ-dependent molecular pathways in neurodegenerative diseases: Review and novel hypotheses
    Aleshin, Stepan
    Strokin, Mikhail
    Sergeeva, Marina
    Reiser, Georg
    [J]. NEUROCHEMISTRY INTERNATIONAL, 2013, 63 (04) : 322 - 330
  • [7] Isoform specific changes in PPARα and β in colon and breast cancer with differentiation
    Aung, CS
    Faddy, HM
    Lister, EJ
    Monteith, GR
    Roberts-Thomson, SJ
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2006, 340 (02) : 656 - 660
  • [8] The Kruppel-like factor KLF2 inhibits peroxisome proliferator-activated receptor-γ expression and adipogenesis
    Banerjee, SS
    Feinberg, MW
    Watanabe, M
    Gray, S
    Haspel, RL
    Denkinger, DJ
    Kawahara, R
    Hauner, H
    Jain, MK
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (04) : 2581 - 2584
  • [9] Lipid metabolic reprogramming in cancer cells
    Beloribi-Djefaflia, S.
    Vasseur, S.
    Guillaumond, F.
    [J]. ONCOGENESIS, 2016, 5 : e189 - e189
  • [10] LIPID METABOLISM IMPAIRMENT IN HUMAN GLIOMAS: EXPRESSION OF PEROXISOMAL PROTEINS IN HUMAN GLIOMAS AT DIFFERENT GRADES OF MALIGNANCY
    Benedetti, E.
    Galzio, R.
    Laurenti, G.
    D'Angelo, B.
    Melchiorre, E.
    Cifone, M. G.
    Fanelli, F.
    Muzi, P.
    Coletti, G.
    Alecci, M.
    Sotgiu, A.
    Ceru, M. P.
    Cimini, A.
    [J]. INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2010, 23 (01) : 235 - 246